SCHEMBL1250231

SCHEMBL1250231

O=C1NC(=O)/C(=C/c2cc(Cl)cc(Cl)c2)S1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 7/20 0.77
PIM2 Q9P1W9 6/20 0.77
DNM1 Q05193 1/20 0.70
IGF1R P08069 2/20 0.68
ADAMTS5 Q9UNA0 1/20 0.63
PIM3 Q86V86 1/20 0.62
MAOA P21397 3/20 0.61
MAOB P27338 2/20 0.61
CISD1 Q9NZ45 2/20 0.61
NAT1 P18440 1/20 0.61
HPGD P15428 2/20 0.61
RAB9A P51151 2/20 0.61
AKR1B1 P15121 1/20 0.61
GSK3B P49841 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
NPC1 O15118 1/20 0.59
HTT P42858 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1250232 1.00 PIM1 (0.77) PIM1PIM2DNM1IGF1RADAMTS5
SCHEMBL261188 0.87 PIM1 (1.00) PIM1PIM2IGF1RPIM3MAOA
SCHEMBL2544039 0.87 PIM1 (1.00) PIM1PIM2IGF1RPIM3MAOA
SCHEMBL261187 0.87 PIM1 (1.00) PIM1PIM2IGF1RPIM3MAOA
SCHEMBL1250348 0.83 PIM1 (1.00) PIM1PIM2IGF1RADAMTS5PIM3
SCHEMBL1250346 0.83 PIM1 (1.00) PIM1PIM2IGF1RADAMTS5PIM3
SCHEMBL2548389 0.83 PIM1 (1.00) PIM1PIM2IGF1RADAMTS5PIM3
SCHEMBL7559789 0.82 PIM1 (0.90) PIM1PIM2IGF1RPIM3MAOA
SCHEMBL7559786 0.82 PIM1 (0.90) PIM1PIM2IGF1RPIM3MAOA
SCHEMBL6785380 0.81 IGF1R (1.00) PIM1PIM2IGF1RADAMTS5PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002062337-A1 THIAZOLIDINEDIONES SMITHKLINE BEECHAM CORPORATION (US) 2002-08-15 WO claimed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
EP-1585541-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-11-14 EP disclosed
EP-1585541-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-11-14 EP disclosed
EP-1429763-B1 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-05-30 EP disclosed
EP-1605967-A1 NOVEL NPH INSULIN PREPARATIONS NOVO NORDISK A/S (DK) 2005-12-21 EP disclosed
EP-1585541-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK A/S (DK) 2005-10-19 EP disclosed
US-20050065066-A1 comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability NOVO NORDISK A/S (DK) 2005-03-24 US disclosed
WO-2004080481-A1 NOVEL NPH INSULIN PREPARATIONS NOVO NORDISK A/S (DK) 2004-09-23 WO disclosed
WO-2004080480-A1 PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN NOVO NORDISK A/S (DK) 2004-09-23 WO disclosed
WO-2004056347-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed
EP-1429763-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-06-23 EP disclosed
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer NOVO NORDISK A/S (DK) 2003-12-11 US disclosed
WO-2003027081-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2003-04-03 WO disclosed
WO-2002062337-A1 THIAZOLIDINEDIONES SMITHKLINE BEECHAM CORPORATION (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer IAPP, IRS1, GPR119 PIM1 4412/4885PIM2 4504/4885DNM1 1963/4885
US-20050065066-A1 comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability IAPP, IRS1, INSR PIM1 3653/4885PIM2 4144/4885DNM1 2571/4885
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand IAPP, IRS1, HBB PIM1 3773/4885PIM2 4301/4885DNM1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.